Phoenix Asia Holdings Ltd Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $7.2M-2.2% YoYTTM through 31 Mar 2026
Net Income -$1.2M-217.0% YoYTTM through 31 Mar 2026
Free Cash Flow -$5.8MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | 21.1% |
| EBITDA Margin | -16.4% |
| Operating Margin | 6.1% |
| Net Margin | -16.7% |
Returns
7.9%ROE
6.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio7.02x
Net Debt-$1.5Mnet cash position
Cash & Equivalents$892.5K
Quality Metrics
Altman Z-Score221.30
Piotroski F-Score1 / 9
FCF Margin-80.1%
Multi-Year Trend
RevenueFY2026: $7.2M
Diluted EPS-$0.06TTMFY2026: $-0.06
Dividend
No dividend
Capital Allocation
Capex Intensity0.6%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Substructure and Construction Services | $3.5M | -7.3% | View detailsThe company is pivoting its business model. On May 4, 2026, Phoenix Asia announced a definitive stock acquisition agreement to acquire 100% of ACEA Pharma, Inc. in an all-stock transaction valued at $1.0 billion, which will transform the company into a pharmaceutical holding entity upon closing. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.